Tags

Type your tag names separated by a space and hit enter

High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
J Cardiovasc Nurs 2008 Jan-Feb; 23(1):8-13JC

Abstract

It has been shown that HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (statins) lower the incidence of a first stroke in patients with coronary heart disease, diabetes, or risk factors for cardiovascular disease. However, it is unknown whether statin therapy could reduce the incidence of a second stroke in patients without evidence of heart disease. This article reviews the results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial, a prospective, randomized, multicentered, double-blind, placebo-controlled, international trial designed to examine the effect of high-dose atorvastatin on secondary stroke prevention. Trial participants (4,731) had experienced a stroke or transient ischemic attack within 1 to 6 months before randomization into the study. Over the 5-year follow-up period, incidence of second stroke or transient ischemic attack was significantly reduced in the atorvastatin treatment group compared with the placebo group. In addition, high-dose atorvastatin therapy significantly decreased major coronary artery and other negative cardiovascular events. The reduction in incidence of secondary stroke was specific to ischemic stroke as opposed to hemorrhagic stroke. Results of the trial are clinically significant and support extension of the latest secondary stroke prevention guidelines to include statin therapy for those patients without coronary heart disease.

Authors+Show Affiliations

College of Nursing, University of Illinois at Chicago, IL 60612, USA. schwertz@uic.eduNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18158500

Citation

Schwertz, Dorie W., and Karen O. Badellino. "High-dose Statin Therapy for Secondary Prevention of Stroke: Stroke Prevention By Aggressive Reduction in Cholesterol Levels Study Review." The Journal of Cardiovascular Nursing, vol. 23, no. 1, 2008, pp. 8-13.
Schwertz DW, Badellino KO. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review. J Cardiovasc Nurs. 2008;23(1):8-13.
Schwertz, D. W., & Badellino, K. O. (2008). High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review. The Journal of Cardiovascular Nursing, 23(1), pp. 8-13.
Schwertz DW, Badellino KO. High-dose Statin Therapy for Secondary Prevention of Stroke: Stroke Prevention By Aggressive Reduction in Cholesterol Levels Study Review. J Cardiovasc Nurs. 2008;23(1):8-13. PubMed PMID: 18158500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review. AU - Schwertz,Dorie W, AU - Badellino,Karen O, PY - 2007/12/26/pubmed PY - 2008/2/9/medline PY - 2007/12/26/entrez SP - 8 EP - 13 JF - The Journal of cardiovascular nursing JO - J Cardiovasc Nurs VL - 23 IS - 1 N2 - It has been shown that HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (statins) lower the incidence of a first stroke in patients with coronary heart disease, diabetes, or risk factors for cardiovascular disease. However, it is unknown whether statin therapy could reduce the incidence of a second stroke in patients without evidence of heart disease. This article reviews the results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial, a prospective, randomized, multicentered, double-blind, placebo-controlled, international trial designed to examine the effect of high-dose atorvastatin on secondary stroke prevention. Trial participants (4,731) had experienced a stroke or transient ischemic attack within 1 to 6 months before randomization into the study. Over the 5-year follow-up period, incidence of second stroke or transient ischemic attack was significantly reduced in the atorvastatin treatment group compared with the placebo group. In addition, high-dose atorvastatin therapy significantly decreased major coronary artery and other negative cardiovascular events. The reduction in incidence of secondary stroke was specific to ischemic stroke as opposed to hemorrhagic stroke. Results of the trial are clinically significant and support extension of the latest secondary stroke prevention guidelines to include statin therapy for those patients without coronary heart disease. SN - 1550-5049 UR - https://www.unboundmedicine.com/medline/citation/18158500/High_dose_statin_therapy_for_secondary_prevention_of_stroke:_stroke_prevention_by_aggressive_reduction_in_cholesterol_levels_study_review_ L2 - http://Insights.ovid.com/pubmed?pmid=18158500 DB - PRIME DP - Unbound Medicine ER -